个性化文献订阅>期刊> Journal of Medicinal Chemistry
 

Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a Promising Novel Medicine To Treat Schizophrenia

  作者 PINARD EMMANUEL; ALANINE ALEXANDER; ALBERATI DANIELA; BENDER MARKUS; BORRONI EDILIO; BOURDEAUX PATRICK; BROM VIRGINIE; BURNER SERGE; FISCHER HOLGER; HAINZL DOMINIK; HALM REMY; HAUSER NICOLE; JOLIDON SYNESE; LENGYEL JUDITH; MARTY HANSPETER; MEYER THIERRY; MOREAU JEANLUC; MORY ROLAND; NARQUIZIAN ROBERT; NETTEKOVEN MATHIAS; NORCROSS ROGER D; PUELLMANN BERND; SCHMID PHILIPP; SCHMITT SEBASTIEN; STALDER HENRI; WERMUTH ROGER; WETTSTEIN JOSEPH G; ZIMMERLI DANIEL  
  选自 期刊  Journal of Medicinal Chemistry;  卷期  2010年53-12;  页码  4603-4614  
  关联知识点  
 

[摘要]The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内